Cargando…

Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China

BACKGROUND: Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising effects on prolonging progression-free survival (PFS) for advanced sarcoma after failure of standard multimodal Therapy. Methylsulfonic apatinib is one of those TKIs which specifically inhibits VEGFR-2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Lu, Guo, Wei, Wang, Ye, Yan, Taiqiang, Ji, Tao, Xu, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889565/ https://www.ncbi.nlm.nih.gov/pubmed/29625604 http://dx.doi.org/10.1186/s12885-018-4303-z

Ejemplares similares

Anorexia, Hypertension, Pneumothorax, and Hypothyroidism: Potential Signs of Improved Clinical Outcome Following Apatinib in Advanced Osteosarcoma
por: Xie, Lu, et al.
Publicado: (2020)

Advanced alveolar soft part sarcoma responds to apatinib
por: Zhou, Yong, et al.
Publicado: (2017)

Apatinib as targeted therapy for sarcoma
por: Li, Feng, et al.
Publicado: (2018)

The efficacy and safety of apatinib in Ewing’s sarcoma: a retrospective analysis in one institution
por: Wang, Yitian, et al.
Publicado: (2018)

The Efficacy and Safety of Apatinib in Advanced Synovial Sarcoma: A Case Series of Twenty-One Patients in One Single Institution
por: Wang, Yitian, et al.
Publicado: (2020)

Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions
por: Tian, Zhichao, et al.
Publicado: (2019)

Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China
por: Li, Feng, et al.
Publicado: (2017)

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
por: Xie, Lu, et al.
Publicado: (2020)

The Efficacy and Safety of Apatinib in Advanced Synovial Sarcoma: A Case Series of Twenty-One Patients in One Single Institution [Corrigendum]
Publicado: (2020)

Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study
por: Wang, Jiaqiang, et al.
Publicado: (2021)

Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

The efficacy and safety of apatinib in metastatic alveolar soft part sarcoma: a case series of six patients in one institution
por: Wang, Yitian, et al.
Publicado: (2019)

Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials: Chinese Sarcoma Study Group Experience
por: Xie, Lu, et al.
Publicado: (2021)

Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial
por: Zhou, Jian-Guo, et al.
Publicado: (2018)

Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study
por: Wang, Yong, et al.
Publicado: (2019)

The off-label use of targeted therapies in sarcomas: the OUTC’S program
por: Eberst, Lauriane, et al.
Publicado: (2014)

The efficacy and safety of apatinib in metastatic alveolar soft part sarcoma: a case series of six patients in one institution [Corrigendum]
Publicado: (2019)

Apatinib with EGFR-TKIs in advanced wild gene-type NSCLC: A case report
por: Wu, Yuan-Peng, et al.
Publicado: (2019)

An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202)
por: Wang, Xiang, et al.
Publicado: (2020)

Off-Label and Off-NCCN Guidelines Uses of Antineoplastic Drugs in China
por: WANG, Weilan, et al.
Publicado: (2013)

Epidemiological characteristics of 1385 primary sacral tumors in one institution in China
por: Wang, Jun, et al.
Publicado: (2020)

Apatinib for Treatment of Inoperable Metastatic or Locally Advanced Chondrosarcoma: What We Can Learn About the Biological Behavior of Chondrosarcoma from a Two-Center Study
por: Xie, Lu, et al.
Publicado: (2020)

Assessment of Efficiency and Safety of Apatinib in Advanced Bone and Soft Tissue Sarcomas: A Systematic Review and Meta-Analysis
por: Long, Zuoyao, et al.
Publicado: (2021)

Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation
por: Zeng, Da-xiong, et al.
Publicado: (2017)

Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two‐Cohort, Phase Ib/II Trial
por: Xu, Jie, et al.
Publicado: (2021)

Effective Treatment of Low-Grade Myofibroblastic Sarcoma with Apatinib: A Case Report and Literature Review
por: Lin, Yan, et al.
Publicado: (2022)

The use of apatinib in treating primary pleural synovial sarcoma: A case report
por: Chen, Sumei, et al.
Publicado: (2019)

Fatal hemoptysis in patients with advanced esophageal cancer treated with apatinib
por: Wang, Wei, et al.
Publicado: (2018)

Efficacy and safety of apatinib in advanced refractory soft tissue sarcoma and association with histologic subtypes: a multicenter retrospective study
por: Wang, Xiangling, et al.
Publicado: (2022)

Apatinib is effective for treatment of advanced hepatocellular carcinoma
por: Kong, Yinlong, et al.
Publicado: (2017)

Apatinib as an alternative therapy for advanced hepatocellular carcinoma
por: Zhang, Xi-Hao, et al.
Publicado: (2020)

A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients
por: Yang, Mi, et al.
Publicado: (2019)

Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy
por: Liao, Zhichao, et al.
Publicado: (2020)

Multiple drugs: Various toxicities, off-label use and no response to off-label therapy: case report
Publicado: (2021)

Radiological characteristics and predisposing factors of venous tumor thrombus in pelvic osteosarcoma: A mono‐institutional retrospective study of 115 cases
por: Liang, Haijie, et al.
Publicado: (2018)

Apatinib mesylate tablet in the treatment of advanced malignant melanoma
por: Yang, Lingge, et al.
Publicado: (2018)

Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
por: Liu, Jieqiong, et al.
Publicado: (2020)

Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China
por: Peng, Wanren, et al.
Publicado: (2020)

Synergistic Lethality Effects of Apatinib and Homoharringtonine in Acute Myeloid Leukemia
por: Shi, Yuanfei, et al.
Publicado: (2022)

Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety
por: Liao, Zhichao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_uf9q8p7h77is4k56gu8g303qv9